Background: Increased left ventricular afterload during peripheral venoarterial-extracorporeal membrane oxygenation (VA-ECMO) support frequently causes hydrostatic pulmonary oedema. Because physiological studies demonstrated left ventricular afterload decrease during VA-ECMO assistance combined with the intra-aortic balloon pump (IABP), we progressively changed our standard practice systematically to associate an IABP with VA-ECMO. This study aimed to evaluate IABP efficacy in preventing pulmonary oedema in VA-ECMO-assisted patients. Methods: A retrospective single-centre study. Results: Among 259 VA-ECMO patients included, 104 received IABP. Weinberg radiological score-assessed pulmonary oedema was significantly lower in IABP + than IABP -patients at all times after ECMO implantation. This protection against pulmonary oedema persisted when death and switching to central ECMO were used as competing risks (subhazard ratio 0.49, 95% confidence interval (CI) 0.33-0.75; P<0.001). Multivariable analysis retained IABP as being independently associated with a lower risk of radiological pulmonary oedema (odds ratio (OR) 0.4, 95% CI 0.2-0.7; P=0.001) and a trend towards lower mortality (OR 0.54, 95% CI 0.29-1.01; P=0.06). Finally, the time on ECMO free from mechanical ventilation increased in IABP + patients (2.2±4.3 vs. 0.7±2.0 days; P=0.0003). Less frequent pulmonary oedema and more days off mechanical ventilation were also confirmed in 126 highly comparable IABP + and IABP -patients, propensity score matched for receiving an IABP. Conclusions: Associating an IABP with peripheral VA-ECMO was independently associated with a lower frequency of hydrostatic pulmonary oedema and more days off mechanical ventilation under ECMO.
Introduction
Peripheral venoarterial-extracorporeal membrane oxygenation (VA-ECMO) is increasingly used as a first-line therapy for refractory cardiogenic shock. 1, 2 It provides easy and rapid cardiocirculatory support at the bedside, even in remote locations with recourse to mobile ECMO units. 3 Hydrostatic pulmonary oedema (PE) is a feared complication of VA-ECMO, occurring in 20-30% of patients. 1, 4 Its pathophysiology results from increased left ventricular (LV) afterload due to the retrograde ECMO blood flow in the aorta. 5, 6 Patients with little or no residual LV ejection on ECMO are at higher risk for this complication. An intraaortic balloon pump (IABP), with diastolic inflation and systolic deflation, was associated with significantly decreased LV afterload in an animal model of VA-ECMO. 7 In an on-off study on VA-ECMO and IABP-equipped patients, we demonstrated a significant reduction of pulmonary artery occlusion pressure (PAOP) with an IABP. 8 Based on those preliminary data, we progressively changed our standard practice to systematically combine an IABP with VA-ECMO for patients with severe cardiogenic shock.
This study was undertaken retrospectively to evaluate hydrostatic PE in a large series of VA-ECMO patients who received an IABP or not.
Methods

Setting
All patients implanted with ECMO for refractory cardiogenic shock from 2007 to 2012 were retrospectively screened for inclusion from the ECMO database of our 18-bed intensive care unit (ICU). Patients with underlying diseases or cannulation types interfering with the evaluation of hydrostatic PE under VA-ECMO and patients implanted with ECMO 7 days before ICU admission were excluded. In accordance with our hospital's institutional review board (Committee for the Protection of Human Subjects) ethical standards, informed consent for demographic, physiological and hospital outcome data analyses was not obtained because this observational study did not modify existing diagnostic or therapeutic strategies. The ICU database is registered with the national data protection authority (CNIL 1950673).
ECMO and IABP management
Management of ECMO-implanted patients in our ICU was described previously. 9 All VA-ECMO devices were surgically inserted with femoral-femoral 23-29F to 15-18F cannulae. An additional 7F catheter was systematically inserted into the femoral artery to prevent leg ischaemia. Pump speed was adjusted to obtain blood flow of 3.5-4.5 L/minute. Intravenous unfractionated heparin was given to maintain the activated partial thromboplastin time at 1.5-2 times normal. Experienced perfusionists checked the circuit daily. Patients were assessed daily for possible ECMO weaning using clinical and echocardiographic criteria as previously described. 10 When implanted, the 40 mL introducer-equipped IABP (CS100, Datascope, Maquet; Getinge Group, Lübeck, Germany) was inserted into the femoral artery contralateral to ECMO. Its adequate position was assessed by chest X-ray; its pumping was set at a 1:1 ratio in automatic mode based on surface electrocardiogram.
Data collection
All data at ECMO implantation and during follow-up were extracted from our ECMO database and patients' electronic medical records. An inotrope score (dobutamine dose (µg/kg/min) + (epinephrine dose (µg/kg/min) + norepinephrine dose (µg/kg/min)) × 100) was used to quantify inotrope use at ECMO implantation. 9 Nonpulsatile ECMO blood flow was defined as pulse pressure less than 15 mmHg and echocardiographically measured aortic velocity time integral (VTI) less than 5 cm. The diuretic dose received under ECMO was expressed in intravenous bumetanide equivalents.
Radiological PE assessment
Computerised chest X-rays were analysed on days 0, 1, 2, 3 and 7 post-ECMO implantation, by two radiologists who were blinded to patients' IABP status and identity. For the blinding procedure of chest X-rays, an opaque rectangle was pasted on the descending aorta to hide the area where an IABP was potentially positioned (Supplementary Figure  1) . Images were analysed in random order. PE was quantified using the Weinberg radiological score. 11, 12 Chest X-rays were divided into four quadrants, each quantified as: 0, normal; 1, interstitial infiltrate; 2, non-confluent infiltrate; 3, condensation; then the four quadrant values were added. A Weinberg score greater than 4 and higher than the previous value defined radiological PE. Kappa values for the radiologists' intra and interobserver degrees of agreement for Weinberg scores, assessed on 100 randomly selected chest X-rays, were 0.78 and 0.77, respectively.
Statistical analyses
Continuous variables, expressed as median (first; third interquartile range; IQR), were compared with Mann-Whitney U tests. Categorical variables, expressed as n (%), were compared with Fisher's exact test. Paired Wilcoxon and McNemar's tests were used for the matched cohort. Two-way analysis of variance was used to compare repeated Weinberg scores between IABP + and IABP -patients. Radiological PE under ECMO was the primary study endpoint. The Fine and Gray method was used to estimate the risk of developing PE, considering death and switching to central cannulation as competing risks. 13, 14 Several sensitivity analyses were conducted. Log-rank tests compared Kaplan-Meier estimates of event-free survival, with censoring of deceased patients or those with explanted ECMO. For multivariable analyses, all factors associated with the dependent variable in univariable analysis with a P<0.2 were included using a backward stepwise logistic regression model. For practical purposes, continuous variables were transformed into categorical variables with the median as the threshold (except for the sepsis-related organ failure assessment (SOFA) score which was trichotomised). All potential explanatory variables included in the multivariable analyses were subjected to a correlation matrix for analysis of collinearity and variables associated among one other were not included in the model. Thereafter, multiple backward stepwise logistic regression analyses eliminated variables with an exit threshold set at P>0.10. Kappa tests were used to determine intra and interobserver Weinberg score agreement.
To minimise the effect of treatment selection bias and potential confounding factors in this observational study, we rigorously adjusted for differences in baseline characteristics by using propensity score matching. 15 All pre-implantation baseline covariates listed in Supplementary Table 2 were used to build the initial logistic regression model predicting IABP insertion. After calculating each patient's propensity score to receive an IABP, we matched IABP + to IAPB -1:1 for the analysis, without replacement, based on the log odds of the propensity score ('logit'). Using the estimated logits, a randomly selected IABP + patient was matched to the IABPpatient with the closest estimated logit value with a maximum 20% difference between the two logits. In the case of ex-aequo patients, controls were matched using the following algorithm: (a) same year ±1 of implantation; (b) same aetiology; and (c) less than 20% difference between inotrope scores. Investigators were blinded to other patients' data during the matching procedure.
P<0.05 defined significance. Analyses were computed with the SPSS v20 statistics package (IBM Corporation, Armonk, NY, USA), Prism 4.0c software (GraphPad Software, La Jolla, CA, USA), SAS v9.3 (SAS Institute Inc., Cary, NC, USA) and R software (R foundation for statistical computing, Vienna, Austria).
Results
Study population
From 2007 to 2012, 259 patients with refractory cardiogenic shock who had received VA-ECMO support in our ICU were included in the study. One hundred and four had received concomitantly an IABP (Figure 1) . The percentage of patients systematically implanted with an IABP and ECMO rose from 22% to 47% across the study period (Supplementary Figure 2) . Patients' demographics, clinical and laboratory data at ECMO implantation are reported in Table 1 . These patients were severely ill, as reflected by their high inotrope scores and lactatemia levels, high frequencies of ECMO implanted under cardiopulmonary resuscitation and patients with a nonpulsatile blood flow after ECMO implantation. IABP + patients were treated more recently, had a higher percentage of acute myocardial infarctions and were slightly less severely ill than IABP -patients.
IABP impact on PE
Although both groups had comparable radiological scores at ECMO implantation, IABP + patients had significantly fewer radiological signs of PE in the days following ECMO initiation ( Figure 2) . Importantly, even when accounting for death and switching to central ECMO as simultaneous competing risks for developing PE, IABP use remained independently associated with a significantly lower risk of developing radiological PE (subhazard ratio 0.49, 95% confidence interval (CI) 0.33-0.75; P<0.001) (Figure 3) . That result remained unchanged after adjusting for aortic VTI and dilated cardiomyopathy as the underlying disease (not shown). Pertinently, IABP + and IABP -groups had comparable diuretic doses, fluid balances, ECMO blood flows and rates of mitral regurgitation more than grade II (Tables 1 and 2 ).
Univariable analysis of factors associated with radiological PE is reported in Supplementary Table 1. Multivariable analyses retained IABP insertion as being less frequently associated with radiological PE, while dilated cardiomyopathy as the underlying aetiology and non-pulsatile blood flow (reflected by aortic VTI <5 cm at ECMO implantation) were independently associated with it ( Figure 4 ).
Factors associated with IABP implantation are listed in Supplementary Table 2 . IABP + and IABP -patients (63 per group) were matched based on their propensity scores to receive an IABP, yielding two groups highly comparable for baseline characteristics (Table 1) . Matched and unmatched patients' characteristics were compared (Supplementary Table 3 ). For the matched cohort, IABP + patients' Weinberg scores over the first 7 days of ECMO support remained significantly lower ( Figure 2 ) and radiological PE (Figure 3 Figure 3) , while PaO 2 /FiO 2 was not different between groups. They needed less recourse to central VA-ECMO and had a higher probability of receiving a LV assist device, although those differences did not reach statistical significance in the matched cohort ( Table 2) .
Predictors of in-ICU death retained by the multivariable logistic-regression model were a McCabe and Jackson score of 2 or greater, myocarditis, inotropic score greater than 100, lactatemia greater than 8 mmol/L and SOFA score tertiles ( Figure 5 ). IABP combined with ECMO was associated with a non-significant trend towards improved survival survival (odds ratio (OR) 0.54, 95% CI 0.29-1.01; P=0.06). IABP-related complications included: minor haemorrhage at the insertion site (14%), minor distal ischaemia (5%), device dysfunction (3%) and insertion-site infection (1%).
Discussion
In this retrospective study on 259 patients who received peripheral VA-ECMO for refractory cardiogenic shock, we found that combining an IABP with ECMO was associated with a lower frequency of radiological PE. This effect persisted after controlling for confounders and adjusting for the competing risks of death and switching to central ECMO. Similar results were also obtained for a selected subpopulation of propensity score (to receive the pump) matched IABP + and IABP -patients. Finally, IABP was associated with more days off MV under ECMO.
Severe hydrostatic PE is a striking complication that occurs in up to 30% of patients on peripheral VA-ECMO support. 1, 4, 16 To date, several options have been described to manage PE in this context: LV unloading using the Impella device, [17] [18] [19] percutaneous LV drainage, [20] [21] [22] [23] percutaneous balloon atrial septostomy, [24] [25] [26] [27] [28] [29] or switching from peripheral VA-ECMO to central circulatory assistance. 1,4,16 However, those techniques are complex, often dangerous and the exorbitant cost of some of the devices used might limit their use. Our results indicate that early IABP-ECMO combination may be a simple way to protect against hydrostatic PE in peripheral VA-ECMO-assisted patients. In a model of circulatory assistance in sheep, IABP adjunction to VA-ECMO was responsible for a 10% LV afterload decrease and spontaneous cardiac output increase. 7 In an on-off study on patients assisted with IABP and VA-ECMO for refractory cardiogenic shock, stopping IABP was associated with a significant rise in PAOP (19±10 vs. 15±8 mmHg; P=0.01). 8 Restarting IABP led to a subsequent PAOP decrease to 6.6±4.3 mmHg in patients whose PAOP exceeded 15 mmHg. This effect was associated with decreased LV end-systolic and end-diastolic dimensions, and significantly lower E/A Doppler mitral valve ratio, indicating IABP-related LV unloading. In another on-off study on six patients given VA-ECMO support for postcardiotomy cardiogenic shock, IABP was also responsible for significantly diminished left atrial pressure. 30 The IABP effect on VA-ECMO-assisted patients' outcomes remains controversial. In a large national database in Japan, IABP combined with peripheral VA-ECMO was associated with a markedly reduced in-hospital mortality compared to VA-ECMO alone (hazard ratio (HR) 0.74. 95% CI 0.63-0.86; P<0.001). 31 Improved overall survival was also suggested in several cohorts of VA-ECMO assisted patients 32, 33 such as ours, albeit not reproduced in others [34] [35] [36] as well as in a meta-analysis of non-randomised studies. 37 Further studies are needed to evaluate the benefit-to-risk ratio of the technique in this particular setting.
The rate of IABP-attributable complications was low for our cohort and comparable with that of other large studies. 34, 38, 39 However, the authors of two recent cohort studies on patients undergoing coronary artery bypass grafting described possibly increased IABP-attributable morbidity, resulting in prolonged ICU stays, higher bleeding rates and prolonged MV duration. 40, 41 Those observations raise questions about the optimal IABP duration. Another important issue would be better to define patients at risk of PE, to optimise the benefit/risk ratio of IABP implantation. In our study, the absence of residual blood flow pulsatility under ECMO and major LV dilation were associated with a higher risk of severe PE.
Our study's strengths include its large population investigated and characterised in detail. We were able to test the roles of numerous potentially confounding factors in three different types of multivariable analyses, and after careful propensity score matching of IABP + and IABP -patients. However, it also has limitations. First, it was a single-centre, retrospective study. Second, because VA-ECMOassisted patients' P a O 2 /FiO 2 ratios depend at all times on the ratio between the patient's spontaneous cardiac output and ECMO flow, FiO 2 on the ECMO oxygenator and ventilatory settings, oxygenation parameters could not be better characterised during PE episodes. However, it should be noted that IABP -patients were ventilated with significantly higher positive end-expiratory pressure to obtain similar P a O 2 /FiO 2 , also suggesting more severe PE. Likewise, lesional PE of other origins might have interfered with our hydrostatic PE findings, because we did not measure pulmonary wedged pressure in our patients. However, all the patients included in this study were suffering from primary cardiogenic shock, and acute respiratory distress syndrome lesions, if they occurred, probably remained marginal and unaffected by IABP presence. Finally, we cannot exclude that the positive impact of IABP observed in this cohort might actually reflect residual confounding not accounted for in our analyses.
In conclusion, based on 259 VA-ECMO patients analysed retrospectively, IABP was independently associated with a lower risk of hydrostatic PE and more days off MV under ECMO. Future randomised studies might allow the better evaluation of the effects of IABP in VA-ECMOassisted patients. 
